Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.44 |
| ▸ | STAT3 | P40763 | 6/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22511915 | 0.86 | STAT3 (0.47) | CRBNCA2DDB1STAT3PDE6D | |
| SCHEMBL24671633 | 0.86 | STAT3 (0.47) | CRBNCA2DDB1STAT3PDE6D | |
| SCHEMBL23915301 | 0.85 | HDAC1 (0.47) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL24671771 | 0.85 | STAT3 (0.48) | CRBNCA2DDB1STAT3PDE6D | |
| SCHEMBL22959685 | 0.85 | STAT3 (0.44) | CRBNCA2DDB1STAT3PDE6D | |
| SCHEMBL24979657 | 0.85 | STAT3 (0.48) | CRBNCA2DDB1STAT3PDE6D | |
| SCHEMBL23946161 | 0.85 | STAT3 (0.48) | CRBNCA2DDB1STAT3PDE6D | |
| SCHEMBL23915135 | 0.85 | CRBN (0.46) | CRBNCA2DDB1STAT3HDAC3 | |
| SCHEMBL26366310 | 0.84 | STAT3 (0.44) | CRBNCA2DDB1STAT3PDE6D | |
| SCHEMBL22959804 | 0.84 | STAT3 (0.45) | CRBNCA2DDB1STAT3PDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885CA2 4617/4885DDB1 1267/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885CA2 4617/4885DDB1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.